Company Description
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally.
The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME.
In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus.
Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis.
The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
| Country | United Kingdom |
| Founded | 2008 |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 524 |
| CEO | Bahija Jallal |
Contact Details
Address: 92 Park Drive, Milton Park Abingdon, OX14 4RY United Kingdom | |
| Phone | 44 12 3543 8600 |
| Website | immunocore.com |
Stock Details
| Ticker Symbol | IMCR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $26.00 |
| CIK Code | 1671927 |
| CUSIP Number | 45258D105 |
| ISIN Number | US45258D1054 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Bahija Jallal Ph.D. | Chief Executive Officer and Executive Director |
| Travis A. Coy M.B.A. | Chief Financial Officer, Executive Vice President and Head of Corporate Development |
| Tina St. Leger | Executive Vice President and Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 25, 2026 | 10-K | Annual Report |
| Feb 25, 2026 | 8-K | Current Report |
| Feb 18, 2026 | 144 | Filing |
| Feb 18, 2026 | 144 | Filing |
| Feb 18, 2026 | 144 | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Jan 30, 2026 | 8-K | Current Report |
| Jan 9, 2026 | 8-K | Current Report |
| Nov 28, 2025 | 8-K | Current Report |
| Nov 24, 2025 | 144 | Filing |